PTG-300
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Polycythemia Vera
Conditions
Polycythemia Vera
Trial Timeline
Feb 2, 2021 → Mar 15, 2023
NCT ID
NCT04767802About PTG-300
PTG-300 is a phase 2 stage product being developed by Protagonist Therapeutics for Polycythemia Vera. The current trial status is completed. This product is registered under clinical trial identifier NCT04767802. Target conditions include Polycythemia Vera.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04767802 | Phase 2 | Completed |
| NCT04516382 | Phase 1 | Completed |
| NCT04202965 | Phase 2 | Completed |
| NCT04054921 | Phase 2 | Completed |
| NCT03802201 | Phase 2 | Completed |
Competing Products
20 competing products in Polycythemia Vera
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sapablursen + Placebo | Ono Pharmaceutical | Phase 3 | 77 |
| Ruxolitinib + Abemaciclib | Eli Lilly | Phase 1 | 33 |
| Bomedemstat | Merck | Phase 2 | 52 |
| Ruxolitinib + Hydroxycarbamide + Interferon-Alpha | Novartis | Phase 3 | 77 |
| ruxolitinib tablets | Novartis | Phase 3 | 77 |
| Ruxolitinib | Novartis | Pre-clinical | 23 |
| Ruxolitinib | Novartis | Phase 3 | 77 |
| Ruxolitinib + BAT | Novartis | Phase 2 | 52 |
| Hydroxyurea | Novartis | Approved | 85 |
| Best Available Therapy + Ruxolitinib | Novartis | Phase 3 | 77 |
| Smac Mimetic LCL161 | Novartis | Phase 2 | 52 |
| PEGASYS + Aspirin | Roche | Phase 2 | 52 |
| RG7388 + Pegasys | Roche | Phase 1 | 33 |
| Idasanutlin | Roche | Phase 2 | 52 |
| PEGASYS + Hydroxyurea + Aspirin | Roche | Phase 3 | 77 |
| Ropeginterferon alfa-2b | PharmaEssentia | Phase 2 | 51 |
| Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen | PharmaEssentia | Phase 3 | 76 |
| Pegylated-Proline-interferon alpha-2b + Best available therapy (BAT) | PharmaEssentia | Phase 3 | 76 |
| Ropeginterferon alfa-2b | PharmaEssentia | Approved | 84 |
| P1101 + Low-dose aspirin | PharmaEssentia | Phase 2 | 51 |